Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

 
• By Cathy Kelly
Boehringer Ingelheim May Face Price Negotiation For Six Drugs In 2026-2028. • Source: Shutterstock

More from Market Access

More from Pink Sheet